JPMorgan initiated coverage on Larimar Therapeutics (NASDAQ:LRMR) with an Overweight rating and a $9.00 price target. The stock currently trades at $3.47, signaling significant upside.
Analyst Tessa Romero set a December 2027 price target. Larimar's lead candidate is nomlabofusp, a therapy for Friedreich's ataxia.
JPMorgan expects topline results from an open-label study in Q2 2026 and FDA feedback on BLA package readiness.
Larimar plans a rolling BLA submission for accelerated approval in June 2026. If approved, nomlabofusp could be the first frataxin replacement therapy, with U.S. launch in H1 2027.
In other news, Larimar held its 2026 Annual Meeting. Citizens, William Blair, Guggenheim, and Wedbush reaffirmed positive ratings.
